COVID-19 recurrent; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19 recurrent) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011f21a, 047B21A and 027B21A) for COVID-19 vaccination.     Concurrent medical conditions included Depression, Asthma and Drug allergy. Concomitant products included BUPROPION, LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) and MONTELUKAST SODIUM (SINGULAIR) for an unknown indication.   On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (COVID-19 recurrent). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 04-May-2022 to 09-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19 recurrent) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 18-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.         Patient had rebound of symptoms: chills, aches, cough, positive home test on 5/18/22 after testing negative on 5/12/22. patient was taking other medications/products within 2 weeks of starting COVID-19 treatment.patient previously received a COVID-19 Vaccine.  Company Comment: This spontaneous case concerns a 55 year old female patient with relevant medical history of Asthma , who experienced Non-serious , unexpected, AESI of Covid  19 which occurred  6 months 17 days post vaccination with the third dose of mRNA-1273. This patient received mRNA-1273 vaccine as Covid 19 vaccine primary series,  dose 1 and dose 2  with reported adverse event of Allergy for dose 1 . The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 04-May-2022 to 09-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. This patient  reported that she had  rebound of symptoms: chills, aches, cough,  tested positive home test on 5/18/22 after testing negative on 5/12/22. This patient also reported that she coordinated with her physician but no details was reported. No other treatment medications , or results of laboratories /diagnostic procedures were reported . Outcome of the event was reported as resolving. The concurrent medical condition of Asthma of this patient may be considered as a confounder for the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns a 55 year old female patient with relevant medical history of Asthma , who experienced Non-serious , unexpected, AESI of Covid  19 which occurred  6 months 17 days post vaccination with the third dose of mRNA-1273. This patient received mRNA-1273 vaccine as Covid 19 vaccine primary series,  dose 1 and dose 2  with reported adverse event of Allergy for dose 1 . The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 04-May-2022 to 09-May-2022 for COVID-19 treatment, at an unspecified dose and frequency.This patient  reported that she had  rebound of symptoms: chills, aches, cough,  tested positive home test on 5/18/22 after testing negative on 5/12/22. This patient also reported that she coordinated with her physician but no details was reported. No other treatment medications , or results of laboratories /diagnostic procedures were reported . Outcome of the event was reported as resolving. The concurrent medical condition of Asthma of this patient may be considered as a confounder for the event. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.